The Latest Breaking News from FDA

This summer, the CDC is expected to release guidelines for the use of doxy-PEP to prevent STIs. But what is it, and why is everyone talking about it now?

Federal regulators are warning consumers that now-recalled lots of the Tydemy birth control pill “may have reduced effectiveness” due to decreased levels of a key ingredient of the product

Unemployment rate drops, but job additions fall short of expectations, impacting Fed's interest rate decisions.

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

"This [FDA] guideline did not discuss spices and no maximum limits for lead are noted for adults"

Women urged to check their contraceptive pills and take action if they've had sex

Z&A report warns of complexities and consequences, explores alternatives to unlock industry growth.

A federal judiciary full of ideological allies is helping Texas block Democratic priorities and advance right-wing legal doctrines. But the bigger prize is conservative control of the rule of law itself.

Novo’s Ozepmic and Wegovy drugs have altered the mission of the 100-year-old Danish pharma firm best known—until now—for insulin.

Medical journals describe all-cause mortality in randomized controlled trials (RCTs) 

An upcoming resupply mission to the International Space Station will include stem cells destined to be grown into tiny, 3D models of the human brain.